Thus, both AMPK activation (through metformin/phenformin) and AMPK inhibition (Compound C/SBI-0206965 derivatives [33]) could be useful in combination treatment regimens for T-ALL patients. This evidence concerns the gene PRKAA1 and acute lymphoblastic leukemia.